Clinical trial
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients…
NCT00134056 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00134056 |
|---|---|
| Title | S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy |
| Official title | Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Cancer, Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | atrasentan hydrochloride, docetaxel, prednisone, placebo |
| Enrollment | 1,038 |
| Start date | Aug 1, 2006 |
| Primary completion | Feb 1, 2016 |
| Completion | Feb 1, 2016 |
| First posted | Aug 24, 2005 |
| Last update posted | Oct 27, 2021 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: